Lower CSF orexin A (hypocretin-1) levels in patients with schizophrenia treated with haloperidol compared to unmedicated subjects.
D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D002352:Carrier Proteins / Q000134:cerebrospinal fluid*; D005260:Female; D006220:Haloperidol / Q000627:therapeutic use*; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D008297:Male; D008875:Middle Aged; D009479:Neuropeptides / Q000134:cerebrospinal fluid*; D000068797:Orexins; D012559:Schizophrenia / Q000134:cerebrospinal fluid* / Q000188:drug therapy*
D014150:Antipsychotic Agents; D002352:Carrier Proteins; C000596229:HCRT protein, human; D047908:Intracellular Signaling Peptides and Proteins; D009479:Neuropeptides; D000068797:Orexins; D006220:Haloperidol